T. Hansel (London, United Kingdom), G. Brusselle (Ghent, Belgium)
Results of the correlation of asthma control test (ACT) with demographic, functional and therapeutic parameters
N. A. Halis, B. Gemicioglu (Istanbul, Turkey)
|  |
Costs of a methodology applied to the ambulatory follow up of patients with continuous asthma in a primary care practice. An observational study using an electronic record with data base linked by the internet
R. M. Pampliega (Buenos Aires, Argentina)
| |
Exhaled nitric oxide (FENO) in the assessment of the safety of allergen immunotherapy (SIT) in asthma patients
J. Hemrmanowicz-Salamon, J. Mazurek, T. Przybylowski, R. Chazan (Warsaw, Portugal)
| |
Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
F. Lavorini, G. A. Fontana, P. Geri, M. Pistolesi (Florence, Italy)
| |
Pharmacological discussion of levocetirizine and cetirizine
N. Frossard, A. Purohit, G. Pauli (Illkirch Cedex, Strasbourg, France)
| |
Effect of drug delivery and receptor affinity on airway hyperresponsiveness in asthma
M. H. Boskabady, P. D. Snashal, S. Adel-Kardan, A. Zarei, S. Tymmori, M. Harati (Mashhad, Islamic Republic Of Iran)
| |
Therapeutical impact of montelukast on exhaled leukotrienes in asthmatic children
V. Petru, P. Cap, K. Kopecka, F. Pehal, M. Maly (Prague, Czech Republic)
| |
Handling and patient preference of dry powder inhalers for asthma and COPD
M. Schulte, P. Haidl, R. Betz, M. Wencker, T. Meyer (Gauting, Schmallenberg, München, Germany)
| |
Efficacy of inhalation from different powder inhalators in COPD patiens with chronic respiratory failure
E. J. Romanski, A. M. Skoczylas, E. Wojda, P. P. Bielen, J. Kolakowski, P. S. Sliwinski (Warsaw, Poland)
| |
A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics
P. UshaRani, Shivprakash, M. Naidu, M. Rao, M. Verma (Panjagutta; Hyderabad, Ahmedabad, India)
| |
Slow particle dissolution may limit lung absorption of inhaled pharmaceuticals in the lungs
P. Ewing, A. Blomgren, S. Eirefelt, P. Andersson, A. Ryrfelt, P. Gerde (Stockholm, Lund, Sweden)
| |
Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD
S. Haeussermann, D. Acerbi, P. Brand, G. Poli, T. Meyer (Gauting, Germany; Parma, Italy)
| |
Novel non-electrostatic valved holding chamber (VHC) has comparable in vitro performance for delivery of beta-2 agonist as similar-sized, pre-washed but non-conducting VHC
M. W. Nagel, K. J. Wiersema, C. C. Doyle, J. P. Mitchell, R. Sharpe (London, Canada; Nottingham, United Kingdom)
| |
Physicochemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions
W. E. Kamin, A. Schwabe, I. Kraemer (Mainz, Germany)
| |
Reduction of nebulization time can be achieved with a new jet nebulizer design
A. Morice, S. Coughlin, K. Nikander, G. S. Smaldone (Cottingham, Cedar Grove, Stony Brook, United States Of America; Bognor Regis, United Kingdom)
| |
The new jet nebuliser family PARI LC SPRINT: a new concept for rapid drug delivery targeting different age groups
M. Hug, A. Bucholski, M. Keller, T. Selzer, M. Luber, R. G. Fischer, J. Zimmermann (Munich, Germany)
| |
Aerosol performance of two ambroxol inhalation products upon nebulisation by the eFlow rapid
M. Tservistas, A. Bucholski, M. Keller (Munich, Germany)
| |
Effect of 3 different nebulisers on the aerosol delivery performance of isotonic disodium comoglycate (IsoCROM)
A. Bucholski, M. Hug, M. Keller (Munich, Germany)
| |
Concentrations of ciclesonide and its metabolites in the human lung after inhalation of 1280 μg ciclesonide
H. Watz, H. Boss, A. Drollmann, R. Nave, T. D. Bethke, H. Magnussen, H. Hoffmann (Grosshansdorf, Konstanz, Heidelberg, Germany)
| |